Ley group from Washington University rendered DOT1L inhibitors to primary AML cells carrying IDH1/2 mutations to investigate whether these molecules could also be active in AML cases that lacking MLL rearrangements [44]. This evidence concerns the gene DOT1L and acute myeloid leukemia.